VINZENZ GRUPPE
     
 

Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.

Mandorfer, M, Kozbial, K, Freissmuth, C, Schwabl, P, Stättermayer, A F, Reiberger, T, Beinhardt, S, Schwarzer, R, Trauner, M, Ferlitsch, A, Hofer, H, Peck-Radosavljevic, M und Ferenci, P (2015) Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Alimentary pharmacology & therapeutics, 42 (6). pp. 707-18. ISSN 1365-2036

Für diesen Eintrag wurde kein Volltext-Dokument angefügt.

Kurzfassung

BACKGROUND Portal hypertension is the strongest predictor of virological response to pegylated interferon (IFN)/ribavirin in patients with chronic hepatitis C (CHC)-related cirrhosis. AIM To investigate the effects of portal pressure assessed by hepatic venous pressure gradient (HVPG) measurement on virological responses in patients treated with IFN-free regimens outside of clinical trials. METHODS Fifty-six patients with CHC and cirrhosis who underwent HVPG measurement before starting an IFN-free therapy were retrospectively studied. Patients were treated with sofosbuvir in combination with daclatasvir (n = 32), ribavirin (n = 12) or simeprevir (n = 11), or the combination of simeprevir/daclatasvir (n = 1), for 12-24 weeks. RESULTS Hepatic venous pressure gradient values ≥10 mmHg and ≥16 mmHg were observed in 41 (73%) and 31 (55%) patients respectively. The distributions of treatment regimens and durations were comparable between patients with or without portal hypertension. Patients with portal hypertension had lower platelet counts and albumin levels, while bilirubin levels, INR, MELD and Child-Pugh scores were higher than in patients without portal hypertension. Importantly, rates of on-treatment virological response and viral kinetics, as well as the rates of sustained virological response 12 weeks after the end of therapy [96% (54/56)] were not affected by portal hypertension. Anti-viral therapy improved liver stiffness, platelet count, serum albumin and bilirubin levels, as well as prothrombin time. CONCLUSIONS This is the first study to demonstrate that IFN-free regimens overcome the negative effect of portal hypertension on virological responses and viral kinetics. Improvements in liver stiffness and platelet count might reflect an anti-portal hypertensive effect of IFN-free treatments.

Typ des Eintrags: Artikel
Bereiche: Ordensklinikum Linz Elisabethinen > Interne 4 - Gastroenterologie & Hepatologie, Stoffwechsel & Ernährungsmedizin, Endokrinologie
Benutzer: Prof. Dr. Rainer Schöfl
Hinterlegungsdatum: 29 Okt 2019 12:32
Letzte Änderung: 29 Okt 2019 12:32
URI: http://eprints.vinzenzgruppe.at/id/eprint/8854

Actions (login required)

Eintrag anzeigen Eintrag anzeigen